In vitro activity of ABT773, a new ketolide derivative exhibiting innovative microbiological properties against well-characterised antibiotic resistant pathogens in Italy

• Published in: International journal of antimicrobial agents Vol. 23; no. 1; pp. 11 - 16
• Main Authors: Bozzolasco, Micaela, Debbia, Eugenio A, Roveta, Simona, Schito, Anna Maria, Marchese, Anna
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 2004; Amsterdam Elsevier; New York, NY
• Subjects: ABT-773; ABT773; Anti-Bacterial Agents - pharmacology; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Drug Resistance, Bacterial; Drug Resistance, Multiple; Enterococcus; Erythromycin resistance; Gram-Negative Bacteria - drug effects; Gram-Positive Bacteria - drug effects; In Vitro Techniques; Italy; Ketolides; Macrolides; Medical sciences; Microbial Sensitivity Tests; Monobactams - pharmacology; Pharmacology. Drug treatments; Staphylococcus - drug effects; Streptococcus; Italy; Europe; ABT773; Erythromycin resistance; Ketolides; Human; Resistance; Antibiotic; Sensitivity resistance; Gram positive bacteria; Antibacterial agent; In vitro; Clinical isolate; Gram negative bacteria
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2003.05.012

The in vitro activity of ABT773, a new ketolide, was assessed against a collection (518) of well-characterised Gram-positive and Gram-negative pathogens and compared with that of other appropriate drugs. ABT773 was active (MIC-90=0.03
mg/l) against the staphylococci tested which included macrolide-resistant but clindamycin susceptible organisms.
Streptococcus pneumoniae,
S. pyogenes and
S. agalactiae were also inhibited (MIC-90 range: <0.0075–0.5
mg/l) irrespective of their antibiotic resistance phenotype.
Enterococcus faecalis was sensitive to ABT773 with the exception of
VanA mutants.
E. faecium showed poor susceptibility to ABT773. The activity of the new ketolide against
Haemophilus influenzae and
Moraxella catarrhalis was comparable with that of the most potent drugs tested. ABT773 displays the characteristics of a promising agent that deserves to be introduced as the empirical therapy of infections caused by the bacterial species tested here, even if they are multiply resistant.